UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share BDSX The NASDAQ Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi ...

Exhibit 99.1 Biodesix Announces Second Quarter 2024 Results and Highlights Q2 2024 revenue grew 51% over Q2 2023 to $17.9 million; Q2 2024 gross profit margin of 78.4%, a 5.7% improvement from Q2 2023; Raises full-year 2024 revenue guidance to $70-72 million from $65-68 million; Q2 24 Net loss, including certain non-cash items, and Adjusted EBITDA improved by 19% and 38% over Q2 2023; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, CO, August 7, 2024 – Biodesix, Inc. (Nasdaq: BDSX), a leading ...

Biodesix, Inc. (NASDAQ:BDSX) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Scott Hutton - CEO Robin Harper Cowie - CFO Chris Brinzey - IR Conference Call Participants Andrew Brackmann - William Blair Kyle Mikson - Canaccord Genuity Thomas Flaten - Lake Street Capital Markets Operator Welcome to the Biodesix Q1 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your ...

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.67%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced a loss of $0.10, delivering a surprise of 9.09%.Over the last four quarters, the company has surpassed c ...

Note 2 – Summary of Significant Accounting Policies Basis of Presentation Restricted cash consists of deposits related to the Company's corporate credit card. As of March 31, 2024 and December 31, 2023, the Company had $0.1 million restricted cash, respectively, which was included in 'Other current assets' in the accompanying condensed balance sheets. Inventory Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to 'Direct costs and expens ...

i biodesix First quarter 2024 Total Revenue of $14.8 million, a year-over-year increase of 64%, and 7th consecutive quarter of >50% growth in Lung Diagnostic test volume; Raised $55 million in gross proceeds from an oversubscribed and upsized underwritten public offering of common stock and concurrent private placement in April 2024; LOUISVILLE, CO, May 8, 2024 – Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced its financial and operating re ...

Start Time: 08:30 January 1, 0000 9:16 AM ET Biodesix, Inc. (NASDAQ:BDSX) Q4 2023 Earnings Conference Call March 01, 2024, 08:30 AM ET Company Participants Scott Hutton - CEO Robin Harper Cowie - CFO Chris Brinzey - IR Conference Call Participants Andrew Brackmann - William Blair Kyle Mikson - Canaccord Genuity Madison Pasterchick - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Biodesix's Fourth Quarter 2023 Earnings Conference Call. [Operator Instructions]. Please be advise ...

LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions and services company, today provided a corporate update and announced its financial and operating results for the fourth quarter and year ended December 31, 2023 (fiscal 2023). “I am exceptionally proud of the Biodesix team and our record of accomplishments in 2023,” said Scott Hutton, CEO of Biodesix. “We were focused on three goals: driving increased revenue through adoption of our Lung Diagnostic tests an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39659 Biodesix, Inc. (Exact name of Registrant as specified in its Charter) Delaware 20-3986492 (State or other jurisdiction of incor ...

Exhibit 99.1 Persistent, high double-digit growth in Lung Diagnostic test volume - growing 65% in FY2023 versus FY2022 - and the sixth consecutive quarter with greater than 50% year-over-year growth; 2024 Total Revenue Guidance of $65 million to $68 million; Conference Call and Webcast Today at 8:30 a.m. ET "I am exceptionally proud of the Biodesix team and our record of accomplishments in 2023," said Scott Hutton, CEO of Biodesix. "We were focused on three goals: driving increased revenue through adoption ...